INR 770.0
(0.82%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | -129.79 Million INR | -227.43% |
2022 | -38.27 Million INR | -134.16% |
2021 | 112.04 Million INR | 626.3% |
2020 | -21.28 Million INR | -184.07% |
2019 | 25.32 Million INR | -60.89% |
2018 | 64.74 Million INR | -43.56% |
2017 | 114.7 Million INR | 27.19% |
2016 | 90.18 Million INR | 7.1% |
2015 | 84.2 Million INR | 21.18% |
2014 | 69.49 Million INR | 29.56% |
2013 | 53.63 Million INR | 18.19% |
2012 | 45.38 Million INR | 0.0% |
2010 | 34.24 Million INR | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q1 | -92.82 Million INR | -12.05% |
2023 FY | -125.3 Million INR | -227.43% |
2023 Q4 | -82.83 Million INR | -374.42% |
2023 Q1 | -21.29 Million INR | -3.9% |
2023 Q2 | 244 Thousand INR | 101.15% |
2023 Q3 | -17.46 Million INR | -7256.15% |
2022 Q3 | -26.58 Million INR | -194.63% |
2022 FY | -38.27 Million INR | -134.16% |
2022 Q1 | 26 Thousand INR | 100.18% |
2022 Q2 | 28.08 Million INR | 107930.77% |
2022 Q4 | -20.49 Million INR | 22.91% |
2021 Q1 | 45.46 Million INR | 624.01% |
2021 FY | 112.04 Million INR | 626.3% |
2021 Q4 | -14.42 Million INR | -134.27% |
2021 Q3 | 42.09 Million INR | 0.83% |
2021 Q2 | 41.75 Million INR | -8.16% |
2020 FY | -21.28 Million INR | -184.07% |
2020 Q1 | -14.16 Million INR | -242.94% |
2020 Q2 | 2.97 Million INR | 120.97% |
2020 Q3 | -19.87 Million INR | -769.29% |
2020 Q4 | -8.67 Million INR | 56.35% |
2019 FY | 25.32 Million INR | -60.89% |
2019 Q4 | 9.9 Million INR | 292.71% |
2019 Q2 | 14.73 Million INR | 163.23% |
2019 Q1 | 5.59 Million INR | -71.42% |
2019 Q3 | 2.52 Million INR | -82.88% |
2018 Q4 | 19.59 Million INR | 2891.01% |
2018 FY | 64.74 Million INR | -43.56% |
2018 Q3 | 655 Thousand INR | 0.0% |
2017 FY | 114.7 Million INR | 27.19% |
2016 Q1 | 21.34 Million INR | 0.0% |
2016 FY | 90.18 Million INR | 7.1% |
2015 FY | 84.2 Million INR | 21.18% |
2014 FY | 69.49 Million INR | 29.56% |
2013 FY | 53.63 Million INR | 18.19% |
2012 FY | 45.38 Million INR | 0.0% |
2010 FY | 34.24 Million INR | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Biocon Limited | 50.83 Billion INR | 100.255% |
Blue Jet Healthcare Limited | 3.37 Billion INR | 103.849% |
Concord Biotech Limited | 6.26 Billion INR | 102.073% |
Dishman Carbogen Amcis Limited | -413 Million INR | 68.572% |
Jubilant Ingrevia Limited | 2.93 Billion INR | 104.415% |
Lyka Labs Limited | 29.13 Million INR | 545.575% |
Panacea Biotec Limited | - INR | Infinity% |
Piramal Pharma Limited | 4.31 Billion INR | 103.008% |
SMS Lifesciences India Limited | 359.47 Million INR | 136.107% |
Supriya Lifescience Limited | 1.57 Billion INR | 108.259% |
Syngene International Limited | 6.46 Billion INR | 102.007% |
TAKE Solutions Limited | -213.49 Million INR | 39.203% |